Masimo’s (MASI) “Equal Weight” Rating Reaffirmed at Wells Fargo & Company

Wells Fargo & Company reissued their equal weight rating on shares of Masimo (NASDAQ:MASI) in a research note issued to investors on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has a $180.00 price target on the medical equipment provider’s stock, down from their previous price target of $190.00.

Several other equities research analysts have also commented on the stock. BTIG Research lowered shares of Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target on the stock. in a report on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Bank of America assumed coverage on Masimo in a research note on Monday, November 17th. They set a “neutral” rating and a $162.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Monday, December 1st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $181.17.

Masimo Trading Up 0.5%

Shares of Masimo stock opened at $175.61 on Wednesday. The company has a market capitalization of $9.43 billion, a P/E ratio of -16.66, a price-to-earnings-growth ratio of 1.77 and a beta of 1.26. The stock has a fifty day simple moving average of $137.72 and a 200 day simple moving average of $142.84. Masimo has a 12-month low of $125.94 and a 12-month high of $194.88. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69.

Institutional Investors Weigh In On Masimo

Hedge funds and other institutional investors have recently bought and sold shares of the business. Naya Capital Management UK Ltd. bought a new stake in shares of Masimo during the 4th quarter valued at $202,984,000. AQR Capital Management LLC increased its position in shares of Masimo by 3,416.5% during the fourth quarter. AQR Capital Management LLC now owns 1,091,326 shares of the medical equipment provider’s stock valued at $141,938,000 after buying an additional 1,060,292 shares during the period. Viking Global Investors LP purchased a new stake in shares of Masimo in the second quarter worth about $129,096,000. Squarepoint Ops LLC boosted its position in shares of Masimo by 738.8% in the third quarter. Squarepoint Ops LLC now owns 620,932 shares of the medical equipment provider’s stock valued at $91,619,000 after acquiring an additional 546,905 shares during the period. Finally, Westfield Capital Management Co. LP grew its stake in Masimo by 75.9% during the second quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider’s stock valued at $198,702,000 after acquiring an additional 509,724 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo News Summary

Here are the key news stories impacting Masimo this week:

• Positive Sentiment: Danaher agreed to acquire Masimo for $180 per share in cash (~$9.9B), giving investors a clear near‑term valuation anchor and a sizeable premium to pre‑deal levels. Danaher To Acquire Masimo Corporation
• Positive Sentiment: Market reaction: MASI surged on the deal (investors captured roughly a ~34% jump when the news broke), and the stock is trading at elevated volume as merger‑arbitrage activity prices in deal close probability and timing. Masimo shares jump 34% after Danaher agrees to buy the company
• Positive Sentiment: Analyst take on the deal: coverage notes Danaher’s purchase presents solid long‑term financial upside and conservative growth assumptions under new ownership, supporting the strategic rationale for the acquisition. Danaher’s Masimo Acquisition: Solid Financials, Conservative Growth Projections
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating but trimmed its price target to $180 (from $190), effectively aligning its target with the cash offer and signaling limited upside beyond the deal price. Wells Fargo rating / Benzinga
• Neutral Sentiment: Founder/management commentary: founder Joe Kiani and company coverage pieces are framing the sale and future under Danaher; such commentary helps set expectations for integration and standalone operations post‑close. Masimo Founder Joe Kiani On The Healthtech Company’s $10 Billion Acquisition
• Negative Sentiment: Multiple law firms have launched investigations and shareholder groups are probing whether Masimo’s board obtained a fair price, creating potential legal/transactional risk that could delay or alter the deal terms. Shareholder Alert: M&A Class Action Firm Investigating Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.